Northland Capmk Has Optimistic View of Brainsway Q3 Earnings

Key Points

• Northland Capital Markets has increased its Q3 2025 earnings estimates for Brainsway, projecting earnings per share of $0.10, up from a previous estimate of $0.06.
• Brainsway reported earnings of $0.10 per share for the last quarter, exceeding analyst expectations of $0.07 and generating revenue of $12.63 million.
• Analysts have differing views on Brainsway, with Northland Securities upgrading their price target to $19.00, while Wall Street Zen downgraded the stock from a "buy" to a "hold" rating.

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) - Northland Capmk raised their Q3 2025 EPS estimates for Brainsway in a report released on Wednesday, August 13th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of $0.10 per share for the quarter, up from their previous forecast of $0.06. The consensus estimate for Brainsway's current full-year earnings is $0.08 per share. Northland Capmk also issued estimates for Brainsway's FY2026 earnings at $0.40 EPS.

Brainsway (NASDAQ:BWAY - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.07 by $0.03. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. The company had revenue of $12.63 million during the quarter, compared to the consensus estimate of $12.34 million. Brainsway has set its FY 2025 guidance at EPS.

A number of other brokerages have also recently commented on BWAY. HC Wainwright upped their price target on shares of Brainsway from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Brainsway from a "hold" rating to a "buy" rating in a research note on Sunday. Finally, Northland Securities upped their price target on shares of Brainsway from $15.00 to $19.00 and gave the company an "outperform" rating in a research note on Thursday, August 14th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $18.00.

Brainsway Stock Performance

BWAY traded up $0.10 during midday trading on Friday, reaching $14.57. The company had a trading volume of 36,786 shares, compared to its average volume of 53,876. The stock has a market cap of $275.37 million, a PE ratio of 56.04 and a beta of 1.42. Brainsway has a 12-month low of $7.06 and a 12-month high of $15.00. The business has a 50-day moving average price of $12.21 and a two-hundred day moving average price of $10.59.

Hedge Funds Weigh In On Brainsway

Institutional investors have recently made changes to their positions in the stock. Lazard Asset Management LLC bought a new position in shares of Brainsway in the 4th quarter worth $44,000. Raymond James Financial Inc. bought a new position in shares of Brainsway during the 2nd quarter valued at $85,000. GAMMA Investing LLC grew its holdings in shares of Brainsway by 720.7% during the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company's stock valued at $89,000 after purchasing an additional 8,216 shares during the last quarter. Palumbo Wealth Management LLC bought a new position in shares of Brainsway during the 1st quarter valued at $111,000. Finally, Trexquant Investment LP bought a new position in shares of Brainsway during the 1st quarter valued at $129,000. Institutional investors own 30.11% of the company's stock.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.